Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024Cancer Research

Abstract PO5-15-07: Integrative proteomics, phosphoproteomics, and RNA profiling revealed novel timeline-dependent vulnerabilities in HER2-positive breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChristina WeiGuy's and St Thomas' NHS Foundation TrustLYLixin YangInstitute of Oncology ResearchKMKrystine MansfieldTranslational Genomics Research Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wei et al. (2024) studied this question.

synapsesocial.com/papers/68e6bea5b6db64358763eabdhttps://doi.org/10.1158/1538-7445.sabcs23-po5-15-07
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS2-10-06: Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy2026
  2. 2Abstract PO3-14-05: Integration of metabolomics and transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+ Breast Cancer2024
  3. 3Abstract PS3-11-20: Tumor-intrinsic signatures associated with response to chemotherapy-free HER2/PD-L1 blockade in HER2-enriched early breast cancer2026
  4. 4Abstract PS3-11-14: Impact of HER2 amplification and Estrogen Receptor Expression on Pathologic Complete Response to Dual Blockade in HER2-Positive Breast Cancer2026
  5. 5Abstract PO1-15-05: Gene expression signature as a predictor of pathological complete response to neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab treatment in locally advanced HER2-positive breast cancer2024